Holen Sie sich die Stockscreener-App
503.71
0.53%
2.56
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$501.15
Offen:
$501.45
24-Stunden-Volumen:
389.55K
Relative Volume:
0.27
Marktkapitalisierung:
$127.64B
Einnahmen:
$11.02B
Nettoeinkommen (Verlust:
$-535.60M
KGV:
-228.96
EPS:
-2.2
Netto-Cashflow:
$-978.00M
1W Leistung:
+1.47%
1M Leistung:
+6.14%
6M Leistung:
+0.78%
1J Leistung:
+25.61%
1-Tages-Spanne:
$498.02
$505.61
1-Wochen-Bereich:
$490.85
$510.77
52-Wochen-Spanne:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
503.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.97 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
654.92 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.17 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.97 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties - BioSpace
3 No-Brainer Stocks to Buy in May - The Motley Fool
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings? - Nasdaq
Vertex Pharmaceuticals (VRTX) Earnings Preview: What to Expect - GuruFocus
Vertex discontinues AAV research for gene therapies - Fierce Biotech
As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith - Fierce Pharma
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group - MSN
What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings - Nasdaq
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
European regulators recommend new drugs from Vertex, Amgen and Jazz - Endpoints News
, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies - marketscreener.com
EMA Backs Vertex Pharmaceuticals' (VRTX) Alyftrek for Cystic Fib - GuruFocus
Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval - insights.citeline.com
Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach - TipRanks
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts - Yahoo Finance
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - MSN
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect - Nasdaq
Vertex Pharmaceuticals’ Q1 2025 Earnings: What To Expect - Barchart.com
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - MSN
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price T - GuruFocus
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts - Benzinga
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price Target | VRTX Stock News - GuruFocus
ToolGen sues Vertex over alleged unlicensed use of CRISPR tech in gene therapy - koreabiomed.com
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy - simplywall.st
ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom - Longview News-Journal
Lobbying Update: $1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Reshma Kewalramani Among TIME’s 100 Most Influential People Of 2025 - IndiaWest
Reshma Kewalramani among 2025 Time 100 most influential people - The American Bazaar
Peering Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga
Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost
Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - marketscreener.com
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - BioSpace
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):